Loading
Colorectal Cancer Surgical Treatments / Ferroptosis and Cancer Prognosis · Journal article
Molecular Oncology · September 7, 2026
Raises a question worth testing. It does not answer one.
This meta-analysis of publicly available RNA-seq datasets identifies candidate genes and immune cell signatures associated with neoadjuvant therapy response in rectal cancer, including TRIM54, PABPC4, and ARMC2 in responders, and ADSS1, MGAT1, and MYC in non-responders. The findings are mechanistic and hypothesis-generating but lack prospective validation, clinical outcome prediction, or biomarker performance metrics required to support clinical utility.
Meta-analysis of bulk RNA-seq datasets. Patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision, stratified by pathological response status (responders vs. non-responders). Intervention: Analysis of transcriptomic profiles associated with response to neoadjuvant chemoradiotherapy. Compared with: Pathological response status (complete response, partial response, or no response).
TRIM54 and PABPC4 upregulated in responder group; ADSS1 and MGAT1 upregulated in non-responder group ARMC2 identified as predictive biomarker upregulated in pathological complete response Responder group showed enrichment of NK cells and CD4+ lymphocytes; immune precursors linked to poor outcome
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These candidate biomarkers and immune signatures may inform future prospective studies to develop predictive classifiers for neoadjuvant response in rectal cancer. However, external validation, functional studies, and clinical outcome association in independent cohorts are required before any clinical application.
Meta-analysis of public transcriptomic data identifying candidate biomarkers and immune signatures associated with neoadjuvant response in rectal cancer, but without clinical validation, prospective design, or outcome prediction model.
As stated by the source record.
These candidate biomarkers and immune signatures may inform future prospective studies to develop predictive classifiers for neoadjuvant response in rectal cancer. However, external validation, functional studies, and clinical outcome association in independent cohorts are required before any clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Neoadjuvant chemoradiotherapy followed by total mesorectal excision is standard for locally advanced rectal cancer, but response varies and current markers are insufficient. This study integrates public bulk RNA-seq data to identify predictive features of response. TRIM54 and PABPC4 were upregulated in the responder group, while ADSS1 and MGAT1 were upregulated in the non-responder group. ARMC2 was identified as a predictive biomarker upregulated in pathological complete response. Responder group showed enrichment of NK cells and CD4+ lymphocytes, while immune precursors were linked to poor outcome. Transcription factor analysis revealed SP1 and NFKB activations in the non-responder group and TCF15 in the responder group. SMAD3 and RDXANK were associated with complete regression, while MYC was dominant in incomplete regression. These findings provide insight into mechanisms underlying therapy response. To our knowledge, this is the first meta-analysis using high-throughput sequencing data, providing a valuable starting point for future rectal cancer research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.